Traders should monitor for upcoming clinical trial initiations or partnerships based on this data, particularly in HER2-low breast cancer. Positive clinical translation could re-rate CRDF given its small market cap. Watch for investor presentations or updates on combination trials.
Price Chart
Executive Summary
Cardiff Oncology presented preclinical data at AACR 2026 showing that its PLK1 inhibitor onvansertib enhances the antitumor activity of trastuzumab deruxtecan (T-DXd) in HER2-low breast cancer models, overcoming resistance and driving tumor regression. The combination demonstrated synergy, complete responses up to 62%, and favorable tolerability. This expands the potential clinical utility of onvansertib beyond its current focus in colorectal cancer.
Key Facts
- Preclinical data show onvansertib + T-DXd combination drives tumor regression in nearly all mice, with complete response rates up to 62% in resistant models
- Combination overcomes resistance in HER2-low breast cancer, including fulvestrant- and CDK4/6i-resistant cells
- Data presented at AACR 2026, a major oncology conference, increasing scientific credibility and visibility
- Onvansertib is already in Phase 2 trials for RAS-mutated mCRC and being studied in multiple other cancers
- T-DXd (Enhertu) is a commercially established ADC with growing use across breast and other cancers
Financial Impact
High optionality value despite early stage; could significantly expand onvansertib's addressable market if clinical trials succeed
Risk Factors
- Preclinical results may not translate to human trials
- Cardiff Oncology has limited financial resources and may need to raise capital
- High competition in ADC and PLK1 inhibitor space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276475 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $1.33 $1.17 | ▲ +12.03% | ▲ +10.84% | $0.8801 (+33.83%) |
Sep 14, 2026 6w ago | 8-K | $1.31 $1.37 | ▲ +4.58% | ▲ +4.47% | $0.8801 (−32.82%) |
Aug 11, 2026 10w ago | Press Release | $0.9900 $0.8979 | ▲ +9.30% | ▲ +8.86% | $0.8801 (+11.10%) |
Jul 16, 2026 14w ago | Insider Cluster | $0.8800 $0.8381 | ▼ −4.76% | ▼ −4.07% | $0.8801 (+0.01%) |
Jul 16, 2026 14w ago | 8-K | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8801 (−0.64%) |
Jul 16, 2026 14w ago | 424B5 | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8801 (−0.64%) |
Jun 22, 2026 18w ago | Insider Cluster | $1.30 $1.25 | ▼ −3.85% | ▼ −1.78% | $0.8801 (−32.30%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.59 $1.18 | ▲ +25.79% | ▲ +26.22% | $0.8801 (+44.65%) |
Jun 3, 2026 20w ago | 8-K | $1.40 $1.48 | ▲ +5.71% | ▲ +9.53% | $0.8801 (−37.14%) |
Jun 2, 2026 21w ago | Press Release | $1.51 $1.53 | ▲ +1.32% | ▲ +4.29% | $0.8801 (−41.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers